Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma.

Galan-Cobo A, Sitthideatphaiboon P, Qu X, Poteete A, Pisegna MA, Tong P, Chen PH, Boroughs LK, Rodriguez MLM, Zhang W, Parlati F, Wang J, Gandhi V, Skoulidis F, DeBerardinis RJ, Minna JD, Heymach JV.

Cancer Res. 2019 Jul 1;79(13):3251-3267. doi: 10.1158/0008-5472.CAN-18-3527. Epub 2019 Apr 30.

PMID:
31040157
2.

The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma.

Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Braas D, Go J, Graeber TG, Parlati F, Demo S, Li R, Walser TC, Gricowski M, Shuman R, Ibarra J, Fridman D, Phelps ME, Badran K, St John M, Bernthal NM, Federman N, Yanagawa J, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB.

Cancer Cell. 2018 May 14;33(5):905-921.e5. doi: 10.1016/j.ccell.2018.04.002.

3.

Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.

Steggerda SM, Bennett MK, Chen J, Emberley E, Huang T, Janes JR, Li W, MacKinnon AL, Makkouk A, Marguier G, Murray PJ, Neou S, Pan A, Parlati F, Rodriguez MLM, Van de Velde LA, Wang T, Works M, Zhang J, Zhang W, Gross MI.

J Immunother Cancer. 2017 Dec 19;5(1):101. doi: 10.1186/s40425-017-0308-4.

4.

Structural Basis for the Inhibitory Effects of Ubistatins in the Ubiquitin-Proteasome Pathway.

Nakasone MA, Lewis TA, Walker O, Thakur A, Mansour W, Castañeda CA, Goeckeler-Fried JL, Parlati F, Chou TF, Hayat O, Zhang D, Camara CM, Bonn SM, Nowicka UK, Krueger S, Glickman MH, Brodsky JL, Deshaies RJ, Fushman D.

Structure. 2017 Dec 5;25(12):1839-1855.e11. doi: 10.1016/j.str.2017.10.007. Epub 2017 Nov 16.

5.

Correction to Discovery of an Inhibitor of the Proteasome Subunit Rpn11.

Perez C, Li J, Parlati F, Rouffet M, Ma Y, Zhou HJ, Mackinnon AL, Chou TF, Deshaies RJ, Cohen SM.

J Med Chem. 2017 Apr 13;60(7):3217. doi: 10.1021/acs.jmedchem.7b00390. Epub 2017 Mar 22. No abstract available.

PMID:
28328205
6.

Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11.

Li J, Yakushi T, Parlati F, Mackinnon AL, Perez C, Ma Y, Carter KP, Colayco S, Magnuson G, Brown B, Nguyen K, Vasile S, Suyama E, Smith LH, Sergienko E, Pinkerton AB, Chung TDY, Palmer AE, Pass I, Hess S, Cohen SM, Deshaies RJ.

Nat Chem Biol. 2017 May;13(5):486-493. doi: 10.1038/nchembio.2326. Epub 2017 Feb 28.

7.

Discovery of an Inhibitor of the Proteasome Subunit Rpn11.

Perez C, Li J, Parlati F, Rouffet M, Ma Y, Mackinnon AL, Chou TF, Deshaies RJ, Cohen SM.

J Med Chem. 2017 Feb 23;60(4):1343-1361. doi: 10.1021/acs.jmedchem.6b01379. Epub 2017 Feb 13. Erratum in: J Med Chem. 2017 Apr 13;60(7):3217.

8.

Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.

Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, Graeber T, Jackson NJ, Czernin J, Emberley E, Gross M, Janes J, Mackinnon A, Pan A, Rodriguez M, Works M, Zhang W, Parlati F, Demo S, Garon E, Krysan K, Walser TC, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB.

Cell Rep. 2017 Jan 17;18(3):601-610. doi: 10.1016/j.celrep.2016.12.061.

9.

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.

Lee SJ, Levitsky K, Parlati F, Bennett MK, Arastu-Kapur S, Kellerman L, Woo TF, Wong AF, Papadopoulos KP, Niesvizky R, Badros AZ, Vij R, Jagannath S, Siegel D, Wang M, Ahmann GJ, Kirk CJ.

Br J Haematol. 2016 Jun;173(6):884-95. doi: 10.1111/bjh.14014. Epub 2016 Apr 12.

10.

Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083).

Zhou HJ, Wang J, Yao B, Wong S, Djakovic S, Kumar B, Rice J, Valle E, Soriano F, Menon MK, Madriaga A, Kiss von Soly S, Kumar A, Parlati F, Yakes FM, Shawver L, Le Moigne R, Anderson DJ, Rolfe M, Wustrow D.

J Med Chem. 2015 Dec 24;58(24):9480-97. doi: 10.1021/acs.jmedchem.5b01346. Epub 2015 Dec 4.

11.

Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.

Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J, Mackinnon AL, Parlati F, Rodriguez ML, Shwonek PJ, Sjogren EB, Stanton TF, Wang T, Yang J, Zhao F, Bennett MK.

Mol Cancer Ther. 2014 Apr;13(4):890-901. doi: 10.1158/1535-7163.MCT-13-0870. Epub 2014 Feb 12.

12.

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.

Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C, Ball AJ, Kirk CJ.

Clin Cancer Res. 2011 May 1;17(9):2734-43. doi: 10.1158/1078-0432.CCR-10-1950. Epub 2011 Mar 1.

13.

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.

Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, Micklem DR, Ruurs P, Sylvain C, Lu Y, Shenk KD, Bennett MK.

Blood. 2009 Oct 15;114(16):3439-47. doi: 10.1182/blood-2009-05-223677. Epub 2009 Aug 11.

14.

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis.

Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, Shwonek P, Parlati F, Demo SD, Bennett MK, Kirk CJ, Groettrup M.

Nat Med. 2009 Jul;15(7):781-7. doi: 10.1038/nm.1978. Epub 2009 Jun 14. Erratum in: Nat Med. 2009 Nov;15(11):1333.

PMID:
19525961
15.

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, Ho MN, Jiang J, Kirk CJ, Laidig GJ, Lewis ER, Lu Y, Muchamuel T, Parlati F, Ring E, Shenk KD, Shields J, Shwonek PJ, Stanton T, Sun CM, Sylvain C, Woo TM, Yang J.

J Med Chem. 2009 May 14;52(9):3028-38. doi: 10.1021/jm801329v.

PMID:
19348473
16.

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK.

Cancer Res. 2007 Jul 1;67(13):6383-91.

17.

i-SNAREs: inhibitory SNAREs that fine-tune the specificity of membrane fusion.

Varlamov O, Volchuk A, Rahimian V, Doege CA, Paumet F, Eng WS, Arango N, Parlati F, Ravazzola M, Orci L, Söllner TH, Rothman JE.

J Cell Biol. 2004 Jan 5;164(1):79-88. Epub 2003 Dec 29.

18.

Drug discovery in the ubiquitin regulatory pathway.

Wong BR, Parlati F, Qu K, Demo S, Pray T, Huang J, Payan DG, Bennett MK.

Drug Discov Today. 2003 Aug 15;8(16):746-54. Review.

PMID:
12944097
19.

Cell cycle regulatory E3 ubiquitin ligases as anticancer targets.

Pray TR, Parlati F, Huang J, Wong BR, Payan DG, Bennett MK, Issakani SD, Molineaux S, Demo SD.

Drug Resist Updat. 2002 Dec;5(6):249-58. Review.

PMID:
12531181
20.

Regulation of membrane fusion by the membrane-proximal coil of the t-SNARE during zippering of SNAREpins.

Melia TJ, Weber T, McNew JA, Fisher LE, Johnston RJ, Parlati F, Mahal LK, Sollner TH, Rothman JE.

J Cell Biol. 2002 Sep 2;158(5):929-40. Epub 2002 Sep 3.

21.

Distinct SNARE complexes mediating membrane fusion in Golgi transport based on combinatorial specificity.

Parlati F, Varlamov O, Paz K, McNew JA, Hurtado D, Söllner TH, Rothman JE.

Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5424-9.

22.

A t-SNARE of the endocytic pathway must be activated for fusion.

Paumet F, Brügger B, Parlati F, McNew JA, Söllner TH, Rothman JE.

J Cell Biol. 2001 Dec 10;155(6):961-8. Epub 2001 Dec 10.

23.

Functional architecture of an intracellular membrane t-SNARE.

Fukuda R, McNew JA, Weber T, Parlati F, Engel T, Nickel W, Rothman JE, Söllner TH.

Nature. 2000 Sep 14;407(6801):198-202.

24.

Topological restriction of SNARE-dependent membrane fusion.

Parlati F, McNew JA, Fukuda R, Miller R, Söllner TH, Rothman JE.

Nature. 2000 Sep 14;407(6801):194-8.

25.

Compartmental specificity of cellular membrane fusion encoded in SNARE proteins.

McNew JA, Parlati F, Fukuda R, Johnston RJ, Paz K, Paumet F, Söllner TH, Rothman JE.

Nature. 2000 Sep 14;407(6801):153-9.

26.

Close is not enough: SNARE-dependent membrane fusion requires an active mechanism that transduces force to membrane anchors.

McNew JA, Weber T, Parlati F, Johnston RJ, Melia TJ, Söllner TH, Rothman JE.

J Cell Biol. 2000 Jul 10;150(1):105-17.

27.

SNAREpins are functionally resistant to disruption by NSF and alphaSNAP.

Weber T, Parlati F, McNew JA, Johnston RJ, Westermann B, Söllner TH, Rothman JE.

J Cell Biol. 2000 May 29;149(5):1063-72.

28.

Putative fusogenic activity of NSF is restricted to a lipid mixture whose coalescence is also triggered by other factors.

Brügger B, Nickel W, Weber T, Parlati F, McNew JA, Rothman JE, Söllner T.

EMBO J. 2000 Mar 15;19(6):1272-8.

29.

Content mixing and membrane integrity during membrane fusion driven by pairing of isolated v-SNAREs and t-SNAREs.

Nickel W, Weber T, McNew JA, Parlati F, Söllner TH, Rothman JE.

Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12571-6.

30.

Rapid and efficient fusion of phospholipid vesicles by the alpha-helical core of a SNARE complex in the absence of an N-terminal regulatory domain.

Parlati F, Weber T, McNew JA, Westermann B, Söllner TH, Rothman JE.

Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12565-70.

31.

Arrangement of subunits in 20 S particles consisting of NSF, SNAPs, and SNARE complexes.

Hohl TM, Parlati F, Wimmer C, Rothman JE, Söllner TH, Engelhardt H.

Mol Cell. 1998 Nov;2(5):539-48.

32.

SNAREpins: minimal machinery for membrane fusion.

Weber T, Zemelman BV, McNew JA, Westermann B, Gmachl M, Parlati F, Söllner TH, Rothman JE.

Cell. 1998 Mar 20;92(6):759-72.

33.

The role of the lectin calnexin in conformation independent binding to N-linked glycoproteins and quality control.

Bergeron JJ, Zapun A, Ou WJ, Hemming R, Parlati F, Cameron PH, Thomas DY.

Adv Exp Med Biol. 1998;435:105-16. Review. No abstract available.

PMID:
9498070
34.
36.

Engineering of papain: selective alteration of substrate specificity by site-directed mutagenesis.

Khouri HE, Vernet T, Ménard R, Parlati F, Laflamme P, Tessier DC, Gour-Salin B, Thomas DY, Storer AC.

Biochemistry. 1991 Sep 17;30(37):8929-36.

PMID:
1892810

Supplemental Content

Loading ...
Support Center